New drug HXN6005 tested in healthy volunteers for first time
NCT ID NCT07449741
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 1 trial tests the safety and tolerability of a single dose of HXN6005 in 32 healthy adults aged 18 to 55. Participants receive either the drug or a placebo and are monitored for side effects and how the drug moves through the body. The study is still recruiting and does not aim to treat any disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- HXN6005
- What could go wrong
- This is an early Phase 1 study in healthy volunteers, so it cannot show any treatment benefit. The drug may prove unsafe or ineffective in later trials.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS (HV) are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Veritus Research
RECRUITINGBayswater, Victoria, 3153, Australia
Contact Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can pulsing light on the scalp boost brain performance?
- Can heavy water reveal how the liver makes fat?
- Which bridge exercise fires up your muscles most? a study investigates
- A new molecule enters human testing: can ZE66-0205 prove safe?
- Reading DNA clues: a blood test that could sniff out lung cancer
- Blood flow restriction may change how hamstrings use oxygen during exercise